English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Diabetic nephropathy (DN) is a major microvascular diabetic complication representing the key leading reason for end-stage renal disease (ESRD). The current work aimed to evaluate the value of urinary and serum NGAL (neutrophil gelatinase-associating lipocalin), as an early biomarker of DN in subjects with type-2 diabetes mellitus (T2DM). The study included 300 adult subjects with T2DM subdivided into 3 groups: Group A: 100 subjects with normoalbuminuria. Group B: 100 subjects with moderately increased albuminuria. Group C: 100 subjects with severely increased albuminuria. Serum NGAL and urinary NGAL were significantly elevated in T2DMsubjects with albuminuria than in normoalbuminuric T2DMsubjects ( p  &lt; 0.001). Serum NGAL and urinary NGAL were positively associated with albumin/creatinine Ratio, ( p  &lt; 0.001). ROC curve analysis was done to discriminate among moderately/severely increased albuminuria from normoalbuminuria showed a cutoff point ≤ 10.76 for serum NGAL with AUC 0.785 ( p  value &lt; 0.001) and a cutoff point ≤ 15.811 with AUC 0.687 for urinary NGAL( p  &lt; 0.001). NGAL can be utilized as a biomarker for the early diagnosis of DN. Both urinary NGAL and serum NGAL may predict albuminuria and can be utilized as a noninvasive tool for diagnosing, grading, and progressions of DN.

NGAL (Neutrophil Gelatinase-Associated Lipocalin) as an early biomarker of nephropathy in patients with type 2 diabetes